Skip to content

A clinical study of hipofen-mediated photodynamic therapy for cholangiocarcinoma

A clinical study of hipofen-mediated photodynamic therapy for cholangiocarcinoma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049107
Enrollment
Unknown
Registered
2021-07-21
Start date
2021-07-21
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholangiocarcinoma

Interventions

Group A:PDT treatment alone
Group B:PDT+ plastic stent placement
Group C:Stent placement alone

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Male or female aged 18 to 85 years; 2.No vascular invasion or metastasis was confirmed by CT, magnetic resonance cholangiopantral imaging, endoscopic ultrasonography and other examinations, and patients who did not conform to the radical surgical treatment plan were comprehensively evaluated. Or patients with radical surgical indications, but refused radical surgical treatment; 3.KPS (Karnofsky performance scale) score >= 50; 4.Sign informed consent and agree to participate in the project.

Exclusion criteria

Exclusion criteria: 1.Patients with severe heart, brain, kidney and other diseases, leukopenia, thrombocytopenia, and malignant tumors of other organs; 2.Patients with unclear consciousness and abnormal mental behavior; 3.Patients who are receiving or have received radiotherapy or chemotherapy for cholangiocarcinoma; 4.Porphyria patients or porphyrin, hipofen allergy; 5.Pregnant, puerperal or lactating women; 6.Patients with advanced stage and spread of tumor.

Design outcomes

Primary

MeasureTime frame
objective remission rate;

Secondary

MeasureTime frame
disease control rate;progression-free survival;overall survival;security;

Countries

China

Contacts

Public ContactLiu Wei

The Second Xiangya Hospital, Central South University

liuweixy@csu.edu.cn+86 13873194825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026